Clinical Trials Logo

Progressive Supranuclear Palsy clinical trials

View clinical trials related to Progressive Supranuclear Palsy.

Filter by:

NCT ID: NCT05067192 Completed - Parkinson Disease Clinical Trials

Optimization of Morphomer-based Alpha-synuclein PET Tracers

Start date: July 15, 2021
Phase:
Study type: Observational

The aim of the project is to develop the first alpha-synuclein (a-syn)-specific PET tracer. The research phase will exploit ACI's proprietary MorphomerTM library and extensively optimized screening workflow. Promising PET-tracer candidates will be tested for their ability in detecting a-syn pathology in patients with a range of Parkinsonian conditions with different a-syn levels and distributions, comprising hereditary forms of PD and other synucleinopathies.

NCT ID: NCT05005819 Recruiting - Healthy Volunteers Clinical Trials

Evaluation of [18F]APN-1607 as a PET Biomarker

Start date: May 25, 2021
Phase: Phase 1
Study type: Interventional

The overall goal of this protocol is to evaluate [18F]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.

NCT ID: NCT04993768 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Start date: October 15, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.

NCT ID: NCT04937530 Recruiting - Clinical trials for Progressive Supranuclear Palsy

RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY

Start date: June 23, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo-controlled trial of RT001 in patients with PSP.

NCT ID: NCT04925622 Completed - Parkinson Disease Clinical Trials

Complex Eye Movements in Parkinson's Disease and Related Movement Disorders

Start date: January 4, 2021
Phase:
Study type: Observational [Patient Registry]

Diagnosing Parkinson's disease (PD) depends on the clinical history of the patient and the patient's response to specific treatments such as levodopa. Unfortunately, a definitive diagnosis of PD is still limited to post-mortem evaluation of brain tissues. Furthermore, diagnosis of idiopathic PD is even more challenging because symptoms of PD overlap with symptoms of other conditions such as essential tremor (ET) or Parkinsonian syndromes (PSs) such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), or vascular Parkinsonism (VaP). Based on the principle that PD and PSs affect brain areas involved in eye movement control, this trial will utilize a platform that records complex eye movements and use a proprietary algorithm to characterize PSs. Preliminary data demonstrate that by monitoring oculomotor alterations, the process can assign PD-specific oculomotor patterns, which have the potential to serve as a diagnostic tool for PD. This study will evaluate capabilities of the process and its ability to differentiate PD from other PSs with statistical significance. The specific aims of this proposal are: To optimize the detection and analysis algorithms, and then to evaluate the process against neurological diagnoses of PD patients in a clinical study.

NCT ID: NCT04883229 Withdrawn - Clinical trials for Progressive Supranuclear Palsy

tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The investigators will test the feasibility of using transcranial direct current stimulation (tDCS) and speech therapy to treat participants with motor speech disorders caused by Frontotemporal Lobar Degeneration Pathology including nonfluent variant Primary Progressive Aphasia, Progressive Supranuclear Palsy, Corticobasal Syndrome, or behavioral variant Frontotemporal Dementia. The investigators will deliver transcranial direct current stimulation (tDCS) either in a clinic setting at the University of California San Francisco, or in patients' homes, via a consumer tDCS device and videoconferencing. Transcranial direct current stimulation (tDCS) is a neuromodulation technique that can enhance the benefits of speech therapy treatment. Participants will receive a dose of tDCS stimulation + speech therapy and a dose of sham tDCS + speech therapy in a randomized double blind crossover study performed either in the clinic or at home via videoconferencing. This study can be performed entirely remotely.

NCT ID: NCT04786158 Completed - Clinical trials for Progressive Supranuclear Palsy

Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)

APOPARKA
Start date: December 1, 2018
Phase:
Study type: Observational

Treatment of tauopathies such as Progressive Supranuclear Palsy (PSP) and Cortico Basal Degeneration (CBD) remains a major challenge. These rare severe neurodegenerative extrapyramidal movement disorders share phenotypic overlap and are usually painful. Parkinson disease (PD) is a common extrapyramidal movement disorder and continuous subcutaneous apomorphine infusion (CSAI) is commonly used in advanced PD patients to alleviate motor and non-motor fluctuations. Effects of subcutaneous apomorphine were investigated especially on pain and, on quality of life in 7 patients with PSD or CBD.This is an observational "real life" surveillance-based study.The Verbal Rating Scale for Pain (VRS) was used to assess changes in pain level and the clinical global impression-improvement scale (CGI-I) was used to assess changes in patient's illness before and during six months of treatment. Detailed report of the symptoms and side effects has been recorded by home nurses throughout the study period.

NCT ID: NCT04753320 Recruiting - Clinical trials for Progressive Supranuclear Palsy

Remote Monitoring in Progressive Supranuclear Palsy (PSP)

Start date: May 5, 2021
Phase:
Study type: Observational

This is a single-arm, longitudinal, observational study on the use of wearable sensors and digital health technology to measure fall frequency and motor, speech, and cognitive function in patients with PSP over the course of approximately one year. Participants will perform supervised remote assessments monthly and in-person assessments approximately every 6 months.

NCT ID: NCT04734379 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

ROCKIT-1
Start date: January 22, 2021
Phase: Phase 2
Study type: Interventional

A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome

NCT ID: NCT04715750 Completed - Alzheimer Disease Clinical Trials

Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity

Start date: November 12, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label study without randomisation. All eligible patients will receive two administrations of the investigational imaging agent [18F]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).